Evidence map›Paper›PMID 39528841›Full record

ArticleAnnals of hematology2025

Early dFLC response by C1D7 predicts complete hematologic response in systemic AL amyloidosis.

Yang Liu, Jingyi Bi, Xuelin Dou, Nan Peng, Lei Wen, Yanqiu Zhao, Xiaojun Huang, Jin Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yang Liu *Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Center of Hematologic Disease, Beijing, 100044, China.
Jingyi Bi *Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Center of Hematologic Disease, Beijing, 100044, China.
Xuelin DouDepartment of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Center of Hematologic Disease, Beijing, 100044, China.
Nan PengDepartment of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Center of Hematologic Disease, Beijing, 100044, China.
Lei WenDepartment of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Center of Hematologic Disease, Beijing, 100044, China.
Yanqiu ZhaoDepartment of Hematology, the first affiliated Hospital of Harbin Medical University, Harbin, China.
Xiaojun HuangDepartment of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Center of Hematologic Disease, Beijing, 100044, China.
Jin LuDepartment of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Center of Hematologic Disease, Beijing, 100044, China. lujin@pku.edu.cn.

Funding

Clinical Medicine Plus X-Young Scholars Project of Peking University PKU2023LCXQ030National Natural Science Foundation of China 82170196Peking University Health Science Center-University of Michigan College of Medicine Joint Institute for Translational and Clinical Research BMU2022JI003
6 · The paper itself

Abstract

Daratumumab and bortezomib, the first-line drugs for AL amyloidosis, typically yield a complete hematologic response (CHR) rate of nearly 60% when used in combinations. An early achievement of CHR is crucial in amyloidosis. We retrospectively evaluated the relationship between dFLC (the difference between free light chain) reduction by Day 7 in Cycle 1 (C1D7) and CHR, organ response, and survival in 48 newly diagnosed AL amyloidosis patients receiving daratumumab, bortezomib, and dexamethasone. The CHR rate within six months was 66.7%. Using Receiver Operating Characteristic Curve curve analysis, we predicted CHR based on a dFLC reduction in C1D7 (67.0% change, optimal sensitivity 87.5%, specificity 81.3%). We introduce the novel concept of "rapid hematologic dFLC response", defined as a reduction in dFLC levels ≥ 67% in C1D7. The CHR rate in rapid responders' groups was higher than that in slow responders' group (90.3% vs. 23.5%, P<0.01). After a median follow-up of 19 months (range: 0.3-57), the renal response rate in rapid responders was higher than that in slow responders (72.0% vs. 27.5%, P = 0.025). The median major organ deterioration event-free survival in the rapid responders' group (not reached) was significantly superior to that in the slow responders' group (19 m, 95% CI: 1.79-23.14 m, P = 0.048). In conclusion, early dFLC reduction in C1D7 indicates a high possibility of CHR and organ response and may allow for early modification of therapy in selected patients.

Indexed as

Antibodies, MonoclonalImmunoglobulin Light-chain AmyloidosisImmunoglobulin Light ChainsAdultAgedAged, 80 and overBortezomibDexamethasoneFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntibodies, MonoclonalBortezomibdaratumumabDexamethasoneImmunoglobulin Light ChainsAL amyloidosisBortezomibDaratumumabRapid hematologic dFLC response

Identifiers

PMID39528841
PMCPMC11868242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.